4 trends tracked about this subject — the full history, oldest to newest below.
The FDA approval of a landmark pancreatic cancer drug costing $480,000 annually signals a shifting economic landscape for oncology treatments.
Patients are facing restricted access to GLP-1 drugs like Ozempic and Wegovy due to high costs and restrictive insurance policies.
A historic healthcare strike at Mass General Brigham concludes with nurses returning to work, though no contract deal has been reached.
Patients are struggling to afford weight loss prescriptions as Massachusetts reduces coverage for these high-cost medications.